Skip to content
Search

Latest Stories

NHSBSA develops tech to tackle potential over-prescription of short course steroid

NHS Business Services Authority (NHSBSA) and partners have devised a system to identify patients who are being prescribed prednisolone due to health risk attached with the medication.

Prednisolone is a short course steroid, which can be crucial in treating respiratory illnesses.


However, recent studies revealed that prescribing too many short course steroids could cause adverse health conditions such as diabetes, cardiovascular illnesses, mental health disorders, musculoskeletal conditions, and many others.

In 2020, more than 35,500 people were prescribed over three grams of prednisolone, considered a high dose.

Darren Curry, chief digital and data officer at NHSBSA, said a lot of work done by the organisation “is around patient safety and to provide the data and access to data which helps to improve patients’ lives.”

For the project, NHSBSA is working in collaboration with Guy’s and St Thomas’ NHS Foundation Trust and the Oxford Academic Health Science Network (Oxford AHSN).

Seema Gadhia, pharmacy lead at Oxford AHSN, said: “Being able to identify people on high cumulative doses of oral corticosteroids, and offer alternative treatment management, has the potential to significantly improve outcomes and reduce the risk of steroid related side effects.”

Grainne d’Ancona, consultant pharmacist and clinical champion for the programme said that oral corticosteroids have a role in managing airways disease, but they must not be mistaken for an inevitable consequence of asthma or COPD.

She said: “Facilitating early identification of those most in need of a review is a crucial step on this path.”

The new metric looks at patients in England who have been prescribed prednisolone tablets, as well as an asthma/COPD medication in the last 12 months. It calculates the total cumulative dose, in milligrams, for the whole period, allowing clinicians to identify anyone at risk.

At-risk patients may be suited to alternative therapies or clinical strategies.

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less